(Alliance News) - Clinigen Group PLC on Thursday said it has launched a managed access programme for Progenics Pharmaceuticals Inc, an oncology company, to provide Azedra outside the US.
Azedra, a radiotherapeutic agent, is approved in the US for the treatment patients 12 years and older with pheochromocytoma or paraganglioma who require systemic anti-cancer therapy. Azedra is not approved for use outside of the US.
Pheochromocytomas and paragangliomas are adrenal gland tumors.
"Clinigen's new partnership with Progenics aligns with our mission to deliver the right medicine to the right patient at the right time," said James Winterman, senior vice president of Unlicensed Medicines at Clinigen.
"Through our global infrastructure and expertise in the supply of unlicensed medicines, eligible patients with pheochromocytomas and paragangliomas will now be able to gain access to this new medicine," added Winterman.
Clinigen Group shares were trading 0.7% lower on Thursday in London at 830.50 pence each.
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2019 Alliance News Limited. All Rights Reserved.
